Lung Cancer Trials Ask AI to find trials
Not Yet RecruitingNot applicableNCT07869329
Official study title

Biomarker Testing to Predict Radiation-Related Heart Disease in Lung Cancer Patients

Study summary

The study will measure serum Pro-N-Cadherin and NT-proBNP (pro B-type natriuretic peptide) levels in adults with non-small cell lung cancer receiving hypofractionated radiation therapy and evaluate whether these biomarkers correlate with radiation dose to the heart, cardiac dysfunction, and adverse cardiac events. Participants will undergo blood collection and echocardiography over a two-year follow-up period.

Ask AI to explain this study
Start here

Key things to know

Main goalDiagnostic

This describes the study’s primary purpose.

What is being studiedSerum Pro-N-Cadherin Biomarker Assessment and Echocardiogram

The study team can explain what participation involves.

Who it may be forNon-small cell lung cancer (NSCLC)

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Oct 9, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Not Yet Recruiting

The study is not accepting participants yet.

What kind of study?Not applicable

Interventional

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?Duke University

Study sponsor

01
Study overview

What this study is about

Purpose
Diagnostic
Study type
Interventional
Phase
Not applicable
Sponsor
Duke University
Interventions being studied
Diagnostic Test: Serum Pro-N-Cadherin Biomarker Assessment; Diagnostic Test: Echocardiogram
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→
Treatment approach
Radiation therapy→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • ≥ 18 years of age
  • Histologic documentation or clinical suspicion of non-small cell lung cancer based on pathology or imaging.
  • Location of disease must be either a central right-sided tumor (defined as tumors with a planning target volume within 2 cm of the primary airways) arising below the level of the heart or any left-sided tumor arising below the level of the heart.
  • Planned to receive hypofractionated radiation therapy (4-18 Gy fractions to a total dose of 45-70 Gy)
  • Planning the target volume that is at or below the most superior aspect of the heart.
  • Willing and able to provide written informed consent
Reasons someone may not be able to joinExclusion criteria
  • Planning to receive concurrent or sequential chemotherapy or immunotherapy
  • Prior radiation therapy to the chest that included more than a minimal dose to the heart (\> 1 Gy mean dose).

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Duke University Medical CenterDurham, North Carolina

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Oct 9, 2026. Always confirm current availability with the study team.

View original record ↗